CCM
CO

Copeland Capital Management’s Global Cord Blood Corporation CO Stock Holding History

Copeland Capital Management’s Portfolio CO Stock Details CO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,671
Closed -$12K – 320
2019
Q1 		$12K Buy
1,671
+77
+5% +$509 ﹤0.01% 209
2018
Q4 		$10K Buy
+1,594
New +$10.2K ﹤0.01% 215

Other funds holding CO

JCM
Jayhawk Capital Management Shawnee, Kansas $59.9M AUM 22.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Copeland Capital Management's CO Position: Q2 2019 in Review

Copeland Capital Management sold out of Global Cord Blood Corporation (CO) in Q2 2019, closing a stake of 1,671 shares — an estimated $12K sold.

Copeland Capital Management first reported a position in CO in Q4 2018 and held it in 2 quarters. The position peaked at $12K in Q1 2019. 40 funds tracked by Wall St. Rank hold CO as of Q2 2019.

  • Copeland Capital Management reported no remaining Global Cord Blood Corporation position as of Q2 2019 after selling out during the quarter.
  • Copeland Capital Management sold 1,671 Global Cord Blood Corporation shares in Q2 2019, an estimated $12K.
  • Copeland Capital Management first reported a position in Global Cord Blood Corporation in Q4 2018 and held it in 2 quarters.
  • Copeland Capital Management's Global Cord Blood Corporation position peaked at $12K in Q1 2019.
  • 40 funds tracked by Wall St. Rank held Global Cord Blood Corporation as of Q2 2019.

Based on Copeland Capital Management's 13F filing for Q2 2019, filed 19 Jul 2019.